Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | CCR5 | P51681 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6399379 | 0.90 | CTSS (0.48) | OPRM1OPRD1OPRK1 | |
| SCHEMBL23554975 | 0.90 | SLC18A3 (0.49) | SLC18A3MEN1KMT2A | |
| SCHEMBL16193284 | 0.86 | CYP3A4 (0.43) | SLC18A3SIGMAR1 | |
| SCHEMBL26629763 | 0.86 | SLC18A3 (0.58) | SLC18A3SIGMAR1CCR5OPRM1OPRD1 | |
| SCHEMBL7103234 | 0.86 | SLC18A3 (0.62) | SLC18A3SIGMAR1CCR5OPRM1OPRD1 | |
| SCHEMBL6399518 | 0.85 | CTSS (0.47) | OPRM1OPRD1OPRK1 | |
| SCHEMBL18800179 | 0.84 | SIGMAR1 (0.43) | SLC18A3SIGMAR1 | |
| SCHEMBL7419921 | 0.84 | SLC18A3 (0.60) | SLC18A3SIGMAR1CCR5OPRM1OPRD1 | |
| Ammonia Solution, Strong SCHEMBL20702116 | 0.84 | SLC18A3 (0.56) | SLC18A3SIGMAR1CCR5OPRM1OPRD1 | |
| SCHEMBL2440428 | 0.84 | SLC18A3 (0.60) | SLC18A3SIGMAR1CCR5OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6949585-B2 | Cyclooctanone derivatives and cyclodecanone derivative, and use thereof | EISAI CO., LTD. (JP) | 2005-09-27 | — | — | US | disclosed |
| US-20040082805-A1 | Cyclooctanone derivatives and cyclodecanone derivative, and use thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1375465-A9 | CYCLOOCTANONE DERIVATIVE AND CYCLODECANONE DERIVATIVE, AND USE THEREOF | Eisai Co., Ltd. (JP) | 2004-04-14 | — | — | EP | disclosed |
| EP-1375479-A1 | PYRROLIDINE DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | Eisai Co., Ltd. (JP) | 2004-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082805-A1 | Cyclooctanone derivatives and cyclodecanone derivative, and use thereof | CCR1, CCL2, CCR5 | SLC18A3 4816/4885SIGMAR1 1365/4885CCR5 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.